Lipideon Biotechnology AG ^None

Lipideon Biotechnology AG is a Swiss company founded in 2002 that focuses on drug research and development for the treatment of arteriosclerosis and related cardiovascular diseases. Their strategy is to create a new class of non-absorbable drugs that inhibit cholesterol absorption in the small intestine, which can reduce serum cholesterol levels and improve the treatment of dyslipidemia. Arteriosclerosis affects more than 50% of the population in Western industrialized nations and is a major health problem. The company was founded as an ETH spin-off by Dr. Helmut Hauser and aims to provide safer and more effective treatments for these conditions.